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disease in addition to the development of cutaneous and
tendon xanthoma.1,3 Heterozygous FH is a relatively
common disorder, occurring in approximately one of
every 500 persons in Japan and in Western countries.
Heterozygous FH causes coronary artery stenosis in the
second decade of life, which progresses more rapidly
than in the general population. The death rate from
coronary artery disease among patients with heterozy-
gous FH is several times higher than that found among
the general population.4 Coronary artery bypass graft-
ing (CABG) has been performed to relieve myocardial
ischemia and to reduce the morbidity and mortality of
myocardial infarction in patients with FH.5 The internal
thoracic artery (ITA) is associated with a rate of long-
term patency superior to that of a saphenous vein graft.
The use of the ITA for the left anterior descending coro-
nary artery has reduced the prevalence of late cardiac
F amilial hypercholesterolemia (FH) is a dominantlyinherited disorder caused by mutations at the locus
for the low-density lipoprotein receptor.1,2 FH is char-
acterized by severe hypercholesterolemia caused by
increased levels of plasma low-density lipoprotein. FH
is frequently associated with premature coronary artery
Objective: Familial hypercholesterolemia is a dominantly inherited disorder
caused by mutations at the locus for the low-density lipoprotein receptor and
is frequently associated with premature coronary artery disease. This study
was performed to determine whether arterial grafting was associated with
long-term benefits for patients with familial hypercholesterolemia.
Methods: During the past 18 years, 101 patients with heterozygous familial
hypercholesterolemia underwent primary coronary artery bypass grafting,
with one hospital death. Group 1 patients (n = 31) received only saphenous
vein grafts. Group 2A patients (n = 47) received one internal thoracic artery
graft and supplemental vein grafts, and group 2B patients (n = 23) had mul-
tiple arterial grafts. After operation, all patients received diet therapy and
intensive cholesterol-lowering drug therapy. Thirteen patients received low-
density lipoprotein apheresis.
Results: During a mean follow-up period of 95 months, 8 patients died, 9
underwent reoperation, and 12 received catheter intervention. The overall
survival was 82% (95% confidence limits, 65%-97%) at 18 years after oper-
ation. The survival in group 2 was higher than that found in group 1 (P =
.01). The overall freedom from major cardiac events (myocardial infarction,
cardiac death, reoperation, and catheter intervention) was 57% (95% confi-
dence limits, 40%-74%) at 16 years after operation. The freedom from reop-
eration in group 2 was higher than that found in group 1 (P = .03). There was
no difference in the survival or freedom from major cardiac events between
groups 2A and 2B.
Conclusion: Arterial grafting improved the long-term freedom from reopera-
tion in patients with familial hypercholesterolemia. Additional benefit of
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events and has improved the late survival after
CABG.6,7 ITA grafting for lesions in the left anterior
descending coronary artery has been advocated, and
additional arterial grafts have been preferable to other
coronary artery systems.8,9 However, the benefit of
arterial grafts has not been clarified in patients with FH
who have rapidly progressing coronary artery disease.
The purpose of this study was to report our 18-year
experience with CABG in 101 patients with heterozy-
gous FH and their long-term outcome and to determine
whether arterial grafting was associated with survival
benefits for patients with FH. The findings in extreme
cases may have important implications for the medical
and surgical treatment of patients with coronary artery
disease.
Patients and methods
The subjects were 101 patients with heterozygous FH who
underwent primary CABG between June 1980 and May 1999
at Kanazawa University Medical Center. The patient group
included 75 men and 26 women who ranged in age from 32
to 77 years, with a mean age of 55 years. FH was diagnosed
according to the following 2 criteria: primary hypercholes-
terolemia (above 230 mg/dL regardless of age group) with
tendon xanthoma and primary hypercholesterolemia with or
without tendon xanthoma in a first-degree relative of patients
with FH.4 All of the patients had heterozygous FH. The mean
level of plasma cholesterol before introduction of cholesterol-
lowering drug therapy was 326 ± 62 mg/dL; the low-density
lipoprotein cholesterol level was 233 ± 71 mg/dL, high-den-
sity lipoprotein level 36 ± 13 mg/dL, and triglyceride level
164 ± 91 mg/dL. Thirty-four of the patients had hypertension,
and 30 had diabetes mellitus. Two patients had 1-vessel dis-
ease, 19 patients had 2-vessel disease, 51 had 3-vessel dis-
ease, and 29 had left main coronary artery disease. The extent
and severity of coronary stenotic changes were assessed by
assigning scores to each of the 15 coronary artery segments,
according to the classification of the American Heart
Association Grading Committee.10 A normal coronary
angiogram was graded 0, stenosis of less than 25% was grad-
ed 1, 25% to 49% stenosis was graded 2, 50% to 74% was
graded 3, and 75% or more stenosis was graded 4. The coro-
nary stenosis index was defined as the sum of these scores.4
The severity of coronary stenosis was graded 0 when postop-
erative angiography indicated complete revascularization of
the target coronary artery. The mean value of the coronary
stenosis index before the operation was 19.8 (range, 8-36).
Forty-three patients had a history of remote myocardial
infarction confirmed by electrocardiographic changes, enzy-
matic changes, or both. Four patients had left ventricular
aneurysms. Five patients had mild aortic valvular stenosis,
and one had aortic valvular regurgitation. One patient had
hypertrophic cardiomyopathy, and one had infective endo-
carditis of the tricuspid valve. The mean left ventricular ejec-
tion fraction was 0.61 (range, 0.18-0.85). Ten patients had
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 5
Kawasuji et al 1009
abdominal aortic aneurysm, 14 had peripheral arterial dis-
ease, and 7 had a history of cerebrovascular disease. Ten
patients had a family history of CABG.
The patients underwent primary CABG procedures with a
total of 82 ITA grafts, 14 gastroepiploic artery grafts, and 162
saphenous vein grafts. The average number of grafts per
patient was 2.6. The patients were divided into 3 groups
according to the type of bypass graft. Thirty-one patients
(group 1) received saphenous vein grafts to major coronary
artery systems. Seventy patients (group 2) received arterial
grafting with or without saphenous vein grafting; 47 of these
patients (group 2A) underwent single arterial grafting, and 23
patients (group 2B) underwent double arterial grafting.
Eleven patients received bilateral ITA grafts to the left anteri-
or descending and circumflex coronary arteries, and 12
patients received both a left ITA graft to the left coronary
artery system and a gastroepiploic artery graft to the right
coronary artery system. Concomitantly, 4 patients underwent
left ventricular aneurysmectomy, 1 received tricuspid valvu-
loplasty, and 1 had graft replacement of the abdominal aortic
aneurysm. The clinical characteristics of the 3 groups are
shown in Table I. Group 2B included a higher percentage of
young male patients than the other groups. The patients of
group 1 received fewer grafts than those of group 2.
After the operation, all patients received diet therapy and
cholesterol-lowering drug therapy with pravastatin, probucol,
or cholestyramine (INN: colestyramine) to reduce their cho-
lesterol level to less than 180 mg/dL and their low-density
lipoprotein cholesterol level to less than 130 mg/dL (Table
II). Thirteen patients who were resistant to drug therapies
received treatment with low-density lipoprotein apheresis
with a dextran-sulfate cellulose column.11 These included 2
patients of group 1 and 11 patients of group 2. The average
duration of follow-up after operation was 95 months (range,
3-226 months; 136 ± 61 months for group 1 and 75 ± 40
months for group 2). Clinical information of survival and
subsequent events was obtained every year by telephone
interview with patients or their physicians. Data are
expressed as means ± SD unless otherwise specified.
Variables were analyzed by using the Student t test, analysis
of variance, and the χ2 test to detect significant (P < .05) dif-
ferences between the measured variables. The survival and
freedom from major cardiac events (myocardial infarction,
cardiac death, reoperation, and catheter intervention) after
operation were calculated by the Kaplan-Meier method and
were analyzed by the Mantel-Cox log-rank test to detect sig-
nificant differences.
Results
One hundred (99%) of the 101 patients successfully
underwent primary CABG. One patient died of graft-
versus-host disease resulting from a blood transfusion.
Coronary angiography was performed within 2 months
after operation in 96 patients. The overall graft patency
after operation was 94% (100% for all 82 ITA grafts
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and 12 of the gastroepiploic arteries and 91% for the
158 saphenous vein grafts). The coronary stenosis
index was reduced from 19.8 ± 5.9 to 6.5 ± 4.2 (P <
.001) after the operation. The mean level of plasma
cholesterol after intensive cholesterol-lowering therapy
was 199 ± 36 mg/dL (P < .001 compared with levels
before treatment); low-density lipoprotein cholesterol
level was 133 ± 34 mg/dL (P < .001), high-density
lipoprotein level 32 ± 11 mg/dL (P = .06), and triglyc-
eride level 115 ± 57 mg/dL (P < .001; Table II).
Treatment with low-density lipoprotein apheresis sig-
nificantly reduced the levels of total cholesterol, low-
density lipoprotein cholesterol, and triglyceride (Table
III). The levels of total cholesterol (P < .001), low-den-
sity lipoprotein cholesterol (P = .03), and triglyceride
(P = .04) after treatment with lipoprotein apheresis
were significantly lower than those for patients who did
not receive treatment.
During the follow-up period, 8 patients died (7 of
cancer and 1 of sudden death). Angina recurred in 25
patients, 2 of whom had a nonfatal myocardial infarc-
tion. The cause of the anginal recurrence was vein
graft atherosclerosis in 15 patients, arterial graft fail-
ure in 3 patients, progression in native coronary steno-
sis in 6 patients, and unknown cause in 1 patient. For
24 patients who underwent coronary angiography
because of recurrent angina, the patency was 87% for
15 ITA grafts, 67% for 3 gastroepiploic artery grafts,
Table I. Clinical characteristics of the 3 groups
Factor Group 1 (n = 31) Group 2A (n = 47) Group 2B (n = 23) P value
Age (y) 56 ± 9 57 ± 10 49 ± 10 .002
Sex (M/F) 21/10 32/15 22/1 .003
Total cholesterol (mg/dL) 323 ± 62 320 ± 58 340 ± 71 .6
LDL cholesterol (mg/dL) 231 ± 67 220 ± 66 273 ± 83 .2
Coronary artery disease .3
One vessel 1 (3%) 1 (2%) 0
Two vessel 4 (13%) 7 (15%) 8 (35%)
Three vessel 14 (45%) 27 (57%) 10 (43%)
Left main trunk 12 (39%) 12 (26%) 5 (22%)
Coronary stenosis index 20.3 ± 6.1 20.1 ± 6.4 18.2 ± 4.4 .5
Left ventricular EF 0.58 ± 0.18 0.61 ± 0.14 0.65 ± 0.11 .3
Prior MI 18 (58%) 19 (40%) 6 (26%) .06
Grafts per patient 2.2 ± 0.7 2.7 ± 0.7 2.7 ± 0.6 .003
LDL, Low-density lipoprotein; EF, ejection fraction; MI, myocardial infarction.
Table II. Changes in plasma lipids and coronary stenosis index after cholesterol-lowering therapy and CABG
Factors Before treatment After treatment Change P value
Total cholesterol (mg/dL) 326 ± 62 199 ± 36 –39% ± 14% <.001
LDL cholesterol (mg/dL) 233 ± 71 133 ± 34 –43% ± 20% <.001
HDL cholesterol (mg/dL) 36 ± 13 32 ± 12 –8% ± 34% .06
Triglyceride (mg/dL) 163 ± 91 115 ± 51 –29% ± 26% <.001
Coronary stenosis index 19.8 ± 5.9 6.5 ± 4.2 –67% ± 18% <.001
LDL, Low-density lipoprotein; HDL, high-density lipoprotein.
Table III. Changes in plasma lipids and coronary stenosis index in 13 patients with FH who underwent CABG and
low-density lipoprotein apheresis
Factors Before treatment After treatment Change P value
Total cholesterol (mg/dL) 378 ± 64 170 ± 26 –55% ± 10% <.001
LDL cholesterol (mg/dL) 285 ± 68 113 ± 37 –62% ± 10% <.001
HDL cholesterol (mg/dL) 35 ± 11 34 ± 9 –6% ± 23% .1
Triglyceride (mg/dL) 167 ± 93 93 ± 47 –38% ± 27% .01
Coronary stenosis index 24.4 ± 5.7 8.3 ± 4.5 –67% ± 15% <.001
LDL, Low-density lipoprotein; HDL, high-density lipoprotein.
survival in group 2 was significantly higher than that
found in group 1 (P = .01). The overall freedom from
major cardiac events (myocardial infarction, cardiac
death, reoperation, and catheter intervention) was 91%
(95% CL, 84%-97%) at 5 years after the operation,
69% (95% CL, 56%-82%) at 10 years, and 60% (95%
CL, 40%-74%) at 16 years (Fig 2). There were no dif-
ferences in the freedom from major cardiac events
between group 1 and group 2 (P = .3) or between group
2A and group 2B (P = .2). There was a tendency toward
a higher freedom from major cardiac events in group 2
than in group 1 eight years after operation. The overall
freedom from reoperation was 84% (95% CL, 72%-
95%) at 10 years after the initial operation and 76%
(95% CL, 62%-91%) at 16 years (Fig 3). The freedom
from reoperation in group 1 was significantly lower
than that found in group 2 (P = .03).
Discussion
This study compared long-term survival and cardiac
events between saphenous vein grafting and arterial
grafting with supplemental vein grafts in patients with
FH. The long-term freedom from reoperation was sig-
nificantly higher in the arterial grafting group than that
found in the vein grafting group, although the inci-
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and 35% for 37 saphenous vein grafts. Postoperative
cholesterol levels (202 ± 51 mg/dL) for patients who
had late cardiac events were not different from those
(199 ± 30 mg/dL) for patients who did not (P = .7).
Nine patients underwent reoperation because of vein
graft atherosclerosis at an average of 8 years (range, 5-
10 years) after the initial operation. These included 8
patients of group 1 and 1 patient of group 2. They
underwent reoperation with 1 or 2 arterial grafts, and
all survived reoperation. Twelve patients underwent
percutaneous transluminal coronary angioplasty at an
average of 4 years (range, 0.5-12 years) after the oper-
ation. These included 4 patients of group 1 and 8
patients of group 2. Four patients underwent graft
replacement of the abdominal aortic aneurysm. Of the
13 patients who had been treated with lipoprotein
apheresis, 3 underwent percutaneous coronary angio-
plasty, but none received reoperation.
The overall survival was 94% (95% confidence lim-
its [CL], 89%-99%) at 5 years after the initial opera-
tion, 90% (95% CL, 82%-97%) at 10 years, and 82%
(95% CL, 65%-97%) at 18 years (Fig 1). There were 7
late deaths in group 1 and 1 late death in group 2. The
Fig 1. Long-term survival of patients with FH who underwent
CABG. A, All patients; B, patients of group 1 and group 2.
The survival in group 2 was significantly (P = .01) higher
than that found in group 1. The number of patients at risk at
selected follow-up intervals is listed beneath panel B. Vertical
bars show 95% confidence limits for the survival estimates.
A
B
Fig 2. Freedom from major cardiac events of patients with
FH who underwent CABG. A, All patients; B, patients of
groups 1 and 2. There was no difference in the freedom from
major cardiac events among the groups.
A
B
dence of major cardiac events could not show signifi-
cant difference between the 2 groups.
A high plasma level of low-density lipoprotein cho-
lesterol is an independent risk factor for coronary artery
disease.3 Nonlipid coronary risk factors, such as hyper-
tension, diabetes, cigarette smoking, and obesity,
appear to be overridden by the more powerful risk fac-
tor of hereditary hypercholesterolemia. Patients with
heterozygous FH constitute a homogeneous group of
patients and are an excellent model for evaluating long-
term outcomes after medical and surgical treatment of
coronary artery disease. Intensive, lipid-lowering drug
therapy reduced the frequency of progression of coro-
nary lesions, increased the frequency of regression, and
reduced the incidence of cardiovascular events in men
with coronary artery disease and high levels of low-
density lipoprotein cholesterol.12 In the Scandinavian
Simvastatin Survival Study of a large number of
patients with coronary heart disease, simvastatin signif-
icantly reduced the incidence of coronary events.13 The
lower the plasma cholesterol levels, the greater the like-
lihood that coronary artery disease can be prevented or
delayed.14 Intensive combination cholesterol-lowering
drug therapy has been advocated as an effective thera-
py for patients with heterozygous FH.15 Low-density
lipoprotein apheresis with a dextran-sulfate cellulose
column is an intensive cholesterol-lowering therapy
that is highly effective and selective in lowering low-
density lipoprotein levels while leaving high-density
lipoprotein levels unchanged.11 A long-term (mean
interval of 6 years) study of patients with FH receiving
low-density lipoprotein apheresis demonstrated that
this therapy significantly decreased coronary events
compared with drug therapy.11 It has been recognized
that CABG improves the long-term survival in patients
with FH.5,16 The issue is whether cholesterol-lowering
therapy is similarly effective for long-term outcomes
after CABG in patients with FH. In a randomized trial
of the Cholesterol Lowering Atherosclerosis Study
over 4 years, combined colestipol-niacin therapy sig-
nificantly decreased new lesions in native coronary
arteries and vein bypass grafts but did not reduce the
progression of vein graft lesions.17 A randomized study
is ethically impossible in patients with FH after the evi-
dence of effectiveness in secondary prevention studies.
The present study could not demonstrate the influence
of cholesterol levels on late cardiac events. However, 13
patients who received lipoprotein apheresis showed
much lower cholesterol levels than the patients who did
not, and 3 of them underwent catheter intervention,
although none underwent reoperation. Further study
may reveal the effectiveness of intensive cholesterol-
lowering therapies for improving long-term results in
surgical patients with FH.
The other important issue is whether arterial graft-
ing contributes to superior results and whether multi-
ple arterial grafting provide additional benefits in
patients with FH. Loop and colleagues6 have demon-
strated a better late cardiac event–free survival after
ITA grafting to the left anterior descending coronary
artery compared with saphenous vein grafting. Galbut
and colleagues8 reported superior results of bilateral
ITA grafting to single ITA grafting. We have prefer-
ably used arterial grafts in our patients with FH over a
13-year period. Despite the high prevalence of extra-
coronary atherosclerotic lesions in patients with FH,
the ITA and the gastroepiploic artery showed no his-
tologic differences from those in patients without
FH.16 In the present study there were 8 late deaths, but
only 1 of them was a cardiac death. Therefore we
could not develop any conclusions regarding differ-
ence in late cardiac death between the groups. The
present study showed that for patients with FH, the
use of a single ITA graft significantly increased the
long-term freedom from reoperation. The effect of
single ITA grafting was so powerful that multiple arte-
rial grafting did not demonstrate any additional bene-
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Fig 3. Freedom from reoperation (Reop) in patients with FH
who underwent CABG. A, All patients; B, patients of group
1 and group 2. The freedom from reoperation in group 2 was
significantly higher than that found in group 1.
A
B
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fits with regard to long-term results in patients with
FH. Comparing single and double ITAs by means of
multivariate analysis, Naunheim and colleagues18
reported that double ITA grafting was not protective
over a 15-year period with regard to survival. Sergeant
and colleagues19 examined whether extensive arterial
grafting beyond a single graft reduced the prevalence
and consequences of myocardial infarction after
CABG in a large series of 9600 patients. Multivariable
analysis showed that arterial grafting lowered the
prevalence of periprocedural, intermediate term, and
late infarction. Although arterial grafting improved the
10-year survival, no additional benefit or cost of
extensive arterial grafting was identified. Lytle and
colleagues20 conducted a long-term (mean follow-up
interval of 10 years) study of patients undergoing
CABG who received either single (8123 patients) or
bilateral ITA grafts (2001 patients). Patients who
received 2 ITA grafts had significantly decreased risks
of death, reoperation, and percutaneous transluminal
coronary angioplasty. Patients with FH in the present
study were relatively young, with a mean age of 55
years. In addition, coronary atherosclerosis in patients
with FH progresses more rapidly than that in the gen-
eral population. We think that intensive cholesterol-
lowering therapies are mandatory for patients with
FH, even in the case of total arterial grafting. Further
follow-up is warranted to determine more accurately
whether multiple arterial grafting is preferable to sin-
gle arterial grafting in patients with FH.
In conclusion, in patients with heterozygous FH, ITA
grafting increased the long-term freedom from reoper-
ation compared with saphenous vein grafting. No addi-
tional benefits of multiple arterial grafting could be
identified.
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Commentary
We compliment Kawasuji and associates on their
management and results over 18 years in 101 patients
with familial hypercholesterolemia and severe coro-
nary artery disease. Seventy patients received one or
more arterial bypass grafts and 30 patients have saphe-
nous vein grafts, for an average of 2.6 grafts per
patient. Postoperatively, the patients’ cholesterol levels
were reduced to less than 180 mg/dL and their low-den-
sity lipoprotein cholesterol levels were reduced to less
than 130 mg/dL with diet therapy and cholesterol-low-
ering drugs. The 13 patients who did not respond to
drug therapy were treated with low-density lipoprotein
apheresis.
This group of patients has premature coronary artery
disease combined with high cholesterol levels and pro-
vides an excellent model to evaluate therapies to opti-
mize results in high-risk patients. Postoperative man-
agement of patients can have an influence on the
incidence of reoperation, and the importance of aggres-
sive control of cholesterol levels should not be ignored.
Aggressive lowering of low-density lipoprotein choles-
terol levels was shown to decrease obstructive changes
in saphenous vein grafts by 31% according to the
National Heart, Lung, and Blood Institute study.1
The effect of maintaining low cholesterol levels in
patients with complete arterial grafting is not known.
Flaker and associates2 showed that a 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitor reduced
clinical events in revascularized postinfarction patients
with average cholesterol levels. This fact, combined
with the knowledge that control of cholesterol levels in
the postoperative period halted the development of new
lesions in native coronary arteries and bypass vein
grafts but did not reduce the progression of vein graft
lesions, has important implications.3 It seems that low-
ering of cholesterol levels is also beneficial in patients
with total arterial grafting, at least in part because of
slowing the development of new lesions. Intensive con-
trol of cholesterol levels in the postoperative period
should be started immediately to prevent the progres-
sion of disease.
Even though this study did not reveal any significant
benefit from multiple arterial grafting, one would sus-
pect that the survival and outcomes would eventually
be affected in view of the low patency in the saphenous
vein grafts. The fact that the internal thoracic artery
(ITA) has a higher patency than venous grafts supports
the importance of arterial grafts. The benefits from total
arterial revascularization will not be seen unless a very
large number of patients are observed for an extended
length of time. Lytle and associates4 reviewed more
than 10,000 patients to show a benefit from bilateral
ITA grafting.
What is not known is whether all arterial conduits are
equivalent. Patency of the ITA, but not that of the radi-
al artery, which differs in that it is a muscular artery,
has proven to be superior. Further long-term studies
into different forms of arterial revascularization will
answer these questions.
This article demonstrates the importance of using
arterial grafts combined with strict control of total and
low-density lipoprotein cholesterol levels in patients
undergoing coronary artery bypass grafting. Current
available data on the beneficial effects of the new statin
drugs only increase the importance of aggressive con-
trol of cholesterol levels in the postoperative patient. As
surgeons, we must educate our patients and their fami-
ly physicians on this vital issue. Striving for ways to
halt progression of native and bypass graft disease may
further decrease the incidence of coronary reoperations
and other morbidities and enhance patient survival.
Alfred J. Tector, MD
Monica L. McDonald, MD
Milwaukee, Wisconsin
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